Vanguard Group
KPTI icon

Vanguard Group’s Karyopharm Therapeutics KPTI Stock Holding History

Vanguard Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.12M Buy
559,619
+151,397
+37% +$926K ﹤0.01% 3327
2025
Q3 		$2.67M Sell
408,222
-110,047
-21% -$592K ﹤0.01% 3490
2025
Q2 		$2.23M Buy
518,269
+7,975
+2% +$39.1K ﹤0.01% 3502
2025
Q1 		$1.91M Sell
510,294
-5
-0% -$43 ﹤0.01% 3506
2024
Q4 		$5.17M Hold
510,299
– – ﹤0.01% 3258
2024
Q3 		$6.35M Hold
510,299
– – ﹤0.01% 3167
2024
Q2 		$6.64M Sell
510,299
-45,594
-8% -$755K ﹤0.01% 3121
2024
Q1 		$12.6M Sell
555,893
-24,784
-4% -$435K ﹤0.01% 2836
2023
Q4 		$7.53M Sell
580,677
-7,318
-1% -$98.6K ﹤0.01% 3106
2023
Q3 		$11.8M Buy
587,995
+9,053
+2% +$203K ﹤0.01% 2786
2023
Q2 		$15.5M Buy
578,942
+78,686
+16% +$3.39M ﹤0.01% 2702
2023
Q1 		$29.2M Buy
500,256
+153,756
+44% +$7.59M ﹤0.01% 2427
2022
Q4 		$17.7M Buy
346,500
+25,607
+8% +$1.78M ﹤0.01% 2677
2022
Q3 		$26.3M Buy
320,893
+39,428
+14% +$2.94M ﹤0.01% 2513
2022
Q2 		$19M Buy
281,465
+17,418
+7% +$1.6M ﹤0.01% 2660
2022
Q1 		$29.2M Buy
264,047
+40,127
+18% +$5M ﹤0.01% 2574
2021
Q4 		$21.6M Sell
223,920
-18,927
-8% -$1.89M ﹤0.01% 2801
2021
Q3 		$21.2M Buy
242,847
+1,958
+0.8% +$203K ﹤0.01% 2831
2021
Q2 		$37.3M Buy
240,889
+3,792
+2% +$550K ﹤0.01% 2523
2021
Q1 		$37.4M Buy
237,097
+5,070
+2% +$1.07M ﹤0.01% 2463
2020
Q4 		$53.9M Buy
232,027
+2,423
+1% +$561K ﹤0.01% 2159
2020
Q3 		$50.3M Sell
229,604
-7,996
-3% -$1.96M ﹤0.01% 2016
2020
Q2 		$67.5M Buy
237,600
+21,036
+10% +$6.22M ﹤0.01% 1853
2020
Q1 		$62.4M Buy
216,564
+32,171
+17% +$8.87M ﹤0.01% 1760
2019
Q4 		$53M Buy
184,393
+1,422
+0.8% +$309K ﹤0.01% 2086
2019
Q3 		$26.4M Sell
182,971
-15,953
-8% -$2.16M ﹤0.01% 2342
2019
Q2 		$17.9M Buy
198,924
+24,639
+14% +$1.98M ﹤0.01% 2567
2019
Q1 		$15.3M Buy
174,285
+59,026
+51% +$6.54M ﹤0.01% 2626
2018
Q4 		$16.2M Sell
115,259
-45,600
-28% -$7.69M ﹤0.01% 2530
2018
Q3 		$41.1M Sell
160,859
-5,355
-3% -$1.48M ﹤0.01% 2242
2018
Q2 		$42.4M Buy
166,214
+37,144
+29% +$9.19M ﹤0.01% 2208
2018
Q1 		$26M Buy
129,070
+8,977
+7% +$1.79M ﹤0.01% 2386
2017
Q4 		$17.3M Buy
120,093
+2,115
+2% +$340K ﹤0.01% 2546
2017
Q3 		$19.4M Buy
117,978
+9,883
+9% +$1.42M ﹤0.01% 2500
2017
Q2 		$14.7M Buy
108,095
+25,644
+31% +$3.8M ﹤0.01% 2593
2017
Q1 		$15.9M Buy
82,451
+7,340
+10% +$1.18M ﹤0.01% 2545
2016
Q4 		$10.6M Buy
75,111
+16,337
+28% +$2.21M ﹤0.01% 2719
2016
Q3 		$8.58M Buy
58,774
+4,344
+8% +$522K ﹤0.01% 2762
2016
Q2 		$5.48M Buy
54,430
+8,515
+19% +$1.11M ﹤0.01% 2930
2016
Q1 		$6.14M Sell
45,915
-889
-2% -$98.1K ﹤0.01% 2853
2015
Q4 		$9.3M Buy
46,804
+253
+0.5% +$54.8K ﹤0.01% 2677
2015
Q3 		$7.35M Sell
46,551
-163
-0.3% -$43.6K ﹤0.01% 2780
2015
Q2 		$19.1M Buy
46,714
+9,244
+25% +$4M ﹤0.01% 2377
2015
Q1 		$17.2M Buy
37,470
+9,757
+35% +$4.21M ﹤0.01% 2387
2014
Q4 		$15.6M Buy
27,713
+2,300
+9% +$1.31M ﹤0.01% 2356
2014
Q3 		$13.3M Buy
25,413
+5,653
+29% +$3.19M ﹤0.01% 2374
2014
Q2 		$13.8M Buy
19,760
+10,187
+106% +$4.74M ﹤0.01% 2370
2014
Q1 		$4.43M Buy
9,573
+4,351
+83% +$2.21M ﹤0.01% 2889
2013
Q4 		$1.79M Buy
+5,222
New +$1.44M ﹤0.01% 3227

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group's KPTI Position: Q4 2025 in Review

Vanguard Group increased its Karyopharm Therapeutics (KPTI) stake by 37% in Q4 2025, buying an estimated $926K and bringing the position to 559,619 shares worth $4.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Vanguard Group first reported a position in KPTI in Q4 2013 and has held it in 49 quarters since. The position peaked at $67.5M in Q2 2020. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Vanguard Group held 559,619 shares of Karyopharm Therapeutics worth $4.12M as of Q4 2025.
  • Vanguard Group bought 151,397 Karyopharm Therapeutics shares in Q4 2025, an estimated $926K.
  • Karyopharm Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3327 holding.
  • Vanguard Group first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 49 quarters since.
  • Vanguard Group's Karyopharm Therapeutics position peaked at $67.5M in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.